X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (39630) 39630
Book Chapter (323) 323
Dissertation (106) 106
Publication (35) 35
Conference Proceeding (29) 29
Government Document (23) 23
Newspaper Article (12) 12
Book / eBook (4) 4
Book Review (4) 4
Magazine Article (4) 4
Web Resource (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (20193) 20193
animals (18024) 18024
hypoxia (10895) 10895
mice (8911) 8911
hypoxia-inducible factor 1, alpha subunit - metabolism (8205) 8205
expression (7520) 7520
male (7452) 7452
biochemistry & molecular biology (7007) 7007
female (6598) 6598
cell biology (6221) 6221
oncology (5534) 5534
cancer (4842) 4842
angiogenesis (4788) 4788
hypoxia-inducible factor 1, alpha subunit - genetics (4598) 4598
gene expression (4576) 4576
cell line, tumor (4340) 4340
apoptosis (4131) 4131
rats (4098) 4098
gene-expression (4040) 4040
signal transduction (3962) 3962
proteins (3930) 3930
activation (3722) 3722
endothelial growth-factor (3382) 3382
cells, cultured (3265) 3265
hypoxia-inducible factor (2997) 2997
cells (2935) 2935
research (2850) 2850
inflammation (2806) 2806
vascular endothelial growth factor (2753) 2753
immunology (2689) 2689
cell hypoxia (2673) 2673
cell line (2651) 2651
oxidative stress (2623) 2623
analysis (2562) 2562
hypoxia-inducible factor 1 (2495) 2495
middle aged (2476) 2476
transcription factors (2453) 2453
immunohistochemistry (2397) 2397
hypoxia-inducible factors (2396) 2396
inducible nitric oxide synthase (2367) 2367
medicine, research & experimental (2355) 2355
pharmacology & pharmacy (2335) 2335
physiological aspects (2299) 2299
vascular endothelial growth factor a - metabolism (2296) 2296
adult (2291) 2291
up-regulation (2259) 2259
hif-1-alpha (2254) 2254
rna, messenger - metabolism (2233) 2233
physiology (2199) 2199
tumors (2180) 2180
gene expression regulation (2092) 2092
hypoxia-inducible factor 1, alpha subunit (2078) 2078
mice, inbred c57bl (2054) 2054
inducible factor-i (2042) 2042
hypoxia-inducible factor-1-alpha (2027) 2027
nf-kappa-b (2009) 2009
cell proliferation (1980) 1980
metabolism (1970) 1970
multidisciplinary sciences (1965) 1965
nitric oxide (1960) 1960
disease models, animal (1959) 1959
blotting, western (1942) 1942
protein (1934) 1934
transcription factors - metabolism (1922) 1922
research article (1914) 1914
biology (1901) 1901
neurosciences (1900) 1900
rodents (1871) 1871
inhibition (1858) 1858
phosphorylation (1854) 1854
growth (1847) 1847
health aspects (1845) 1845
hypoxia - metabolism (1817) 1817
metastasis (1816) 1816
genes (1809) 1809
oxygen (1809) 1809
aged (1777) 1777
hif-1α (1758) 1758
genetic aspects (1744) 1744
gene expression regulation, neoplastic (1735) 1735
reverse transcriptase polymerase chain reaction (1713) 1713
transcription (1705) 1705
rna, messenger - genetics (1687) 1687
molecular sequence data (1673) 1673
medicine (1672) 1672
time factors (1657) 1657
induction (1646) 1646
kinases (1616) 1616
hif-1 (1614) 1614
oxygen - metabolism (1592) 1592
rats, sprague-dawley (1584) 1584
hif-1 alpha (1579) 1579
hypoxia-inducible factor-1 (1539) 1539
gene (1536) 1536
factor-i (1521) 1521
nitric-oxide synthase (1503) 1503
base sequence (1475) 1475
transfection (1468) 1468
in-vivo (1438) 1438
genetics & heredity (1431) 1431
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (39874) 39874
Chinese (318) 318
Japanese (285) 285
Russian (60) 60
Korean (53) 53
French (38) 38
Spanish (37) 37
German (26) 26
Polish (23) 23
Czech (10) 10
Ukrainian (8) 8
Persian (5) 5
Portuguese (4) 4
Italian (3) 3
Swedish (2) 2
Turkish (2) 2
Bulgarian (1) 1
Dutch (1) 1
Hungarian (1) 1
Slovak (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of cellular and molecular medicine, ISSN 1582-1838, 2013, Volume 17, Issue 1, pp. 30 - 54
Accumulating lines of experimental evidence have revealed that hypoxia‐inducible factors, HIF‐1α and HIF‐2α... 
Hypoxia‐inducible factors | Targeted therapies | Cancer‐initiating cells | Hypoxia | Cancer progression | Metabolic pathways | Cancer stem/progenitor cells | Metastasis‐initiating cells | Metastases | Hypoxia-inducible factors | Cancer-initiating cells | Metastasis-initiating cells | MEDICINE, RESEARCH & EXPERIMENTAL | CLINICALLY RELEVANT SUBTYPES | PANCREATIC-CANCER | Cancer stem | progenitor cells | CHRONIC MYELOID-LEUKEMIA | INHIBITS TUMOR-GROWTH | CELL BIOLOGY | EPITHELIAL-MESENCHYMAL TRANSITION | BREAST-CANCER | PROSTATE-CANCER | GENE-EXPRESSION | FATTY-ACID SYNTHASE | ENDOTHELIAL GROWTH-FACTOR | Neoplasms - metabolism | Hypoxia - drug therapy | Neoplastic Stem Cells - drug effects | Humans | Gene Expression Regulation, Neoplastic | Molecular Targeted Therapy | Hypoxia - metabolism | Intercellular Signaling Peptides and Proteins - metabolism | Neoplasm Metastasis | Basic Helix-Loop-Helix Transcription Factors - metabolism | Neoplasms - genetics | Neoplastic Stem Cells - metabolism | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Neoplastic Stem Cells - pathology | Antineoplastic Agents - pharmacology | Basic Helix-Loop-Helix Transcription Factors - genetics | Signal Transduction | Hypoxia-Inducible Factor 1, alpha Subunit - genetics | Intercellular Signaling Peptides and Proteins - genetics | Transcription Factors - genetics | Neoplasms - drug therapy | Transcription Factors - metabolism | Hypoxia - genetics | Hypoxia - pathology | Cell Transformation, Neoplastic - drug effects | Neoplasms - pathology | Apoptosis | Prevention | Glucose metabolism | Physiological aspects | Development and progression | Genetic transcription | Metastasis | Transforming growth factors | Vascular endothelial growth factor | Cancer | Energy metabolism | Transcription factors | Mesenchyme | AKT protein | Insulin-like growth factors | Kinases | Autophagy | Cancer therapies | Neoplasms | Proteins | Homing | Angiogenesis | Signal transduction | Receptors | Epidermal growth factor | Bone marrow | Tumor necrosis factor-TNF | miRNA | Growth factors | Deprivation | Cell survival | Cytokines | Epidermal growth factor receptors | Breast cancer | Rapamycin | Metabolism | Gene expression | Cell differentiation | Insulin | CXCR4 protein | 1-Phosphatidylinositol 3-kinase | Signaling | Pancreatic cancer | Stem cells | Glycolysis | Regulation | Prostate | Cell migration | Tumors | Reviews
Journal Article
Nutrition, ISSN 0899-9007, 2016, Volume 32, Issue 2, pp. 174 - 178
Abstract Flavonoid resveratrol modulates the transcription factor NF-κB; inhibits the cytochrome P450 isoenzyme CYP1 A1... 
Gastroenterology and Hepatology | Obesity | Flavonoids | Microbiota | Type 2 diabetes mellitus | Alzheimer's disease | Resveratrol | CELLS | OXIDATIVE STRESS | RISK-FACTORS | MITOCHONDRIAL-FUNCTION | ENDOPLASMIC-RETICULUM STRESS | INDUCTION | AUTOPHAGY | SIRT1 | NUTRITION & DIETETICS | INSULIN-RESISTANCE | MOUSE MODEL | Autistic Disorder - chemically induced | Tumor Necrosis Factor-alpha - metabolism | Brain-Derived Neurotrophic Factor - genetics | Apoptosis - drug effects | Humans | Tumor Necrosis Factor-alpha - genetics | Cytochrome P-450 CYP1A1 - antagonists & inhibitors | Hypoxia-Inducible Factor 1, alpha Subunit - antagonists & inhibitors | Lipoxins - pharmacology | NF-kappa B - metabolism | Vascular Endothelial Growth Factor A - metabolism | Stilbenes - pharmacology | Metabolic Syndrome - chemically induced | Vascular Endothelial Growth Factor A - genetics | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Brain-Derived Neurotrophic Factor - metabolism | Hypoxia-Inducible Factor 1, alpha Subunit - genetics | Diabetes Mellitus, Type 2 - prevention & control | Gastrointestinal Tract - microbiology | Interleukin-17 - genetics | Gastrointestinal Tract - drug effects | Antioxidants - pharmacology | Autistic Disorder - prevention & control | Transcription Factors - genetics | Cytochrome P-450 CYP1A1 - metabolism | Transcription Factors - metabolism | Interleukin-17 - metabolism | Gastrointestinal Microbiome - drug effects | Interleukin-17 - antagonists & inhibitors | NF-kappa B - genetics | Cell Differentiation - drug effects | Metabolic Syndrome - prevention & control | Cell Proliferation - drug effects | Diabetes Mellitus, Type 2 - chemically induced | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Type 2 diabetes | COX-2 inhibitors | Bisphenol-A | Endothelial growth factors | Microbiota (Symbiotic organisms) | Cytochrome P-450 | Schizophrenia | Bipolar disorder | T cells | Cell differentiation | Fatty acids | Autism | Stem cells | Tumor proteins | Pathogenesis | p53 Protein | Lipids | Proteins | Antioxidants | Signal transduction | Lymphocytes | Rodents | Oxidation | Growth factors | Cytochromes P450 | Diabetes mellitus | Rapamycin | Metabolism | Bisphenol A | Alloxan | Brain-derived neurotrophic factor | Insulin resistance | Hypoxia | Diabetes | Alzheimers disease | Autoimmune diseases | Metabolic disorders | Dementia | Apoptosis | Tumors
Journal Article
Biochemical journal, ISSN 1470-8728, 2013, Volume 451, Issue 3, pp. 427 - 437
The compound BAY 11-7082 inhibits IκBα [inhibitor of NF-κB (nuclear factor κB)α] phosphorylation in cells and has been used to implicate the canonical IKKs (IκB kinases) and NF-κB in >350 publications... 
Linear ubiquitin assembly complex (LUBAC) | Myeloid differentiation factor 88 (MyD88) | Nuclear factor κB (NF-κB) | Lymphoma | Ubiquitin conjugating 13 (Ubc13) | Proteasome | nuclear factor kappa B (NF-kappa B) | proteasome | ACTIVATION | CELL LYMPHOMA-CELLS | LINEAR POLYUBIQUITIN CHAINS | linear ubiquitin assembly complex (LUBAC) | BIOCHEMISTRY & MOLECULAR BIOLOGY | lymphoma | KINASE | IKK | myeloid differentiation factor 88 (MyD88) | CROSS-TALK | IN-VIVO | CONJUGATING ENZYMES | NF-KAPPA-B | NEMO | ubiquitin conjugating 13 (Ubc13) | Nitriles - pharmacology | Humans | Receptors, Interleukin-1 - genetics | Ubiquitin - metabolism | Molecular Sequence Data | Hypoxia-Inducible Factor 1, alpha Subunit - antagonists & inhibitors | I-kappa B Proteins - metabolism | Sulfones - pharmacology | Proteasome Endopeptidase Complex - drug effects | Ubiquitination - drug effects | Hypoxia-Inducible Factor 1, alpha Subunit - metabolism | Myeloid Differentiation Factor 88 - antagonists & inhibitors | Amino Acid Sequence | NF-KappaB Inhibitor alpha | Ubiquitin - antagonists & inhibitors | NF-kappa B p50 Subunit - metabolism | Hypoxia-Inducible Factor 1, alpha Subunit - genetics | Myeloid Differentiation Factor 88 - genetics | Ubiquitin-Conjugating Enzymes - genetics | Macrophages - cytology | Interleukin-1 - pharmacology | Receptors, Interleukin-1 - metabolism | Gene Expression Regulation - drug effects | Macrophages - metabolism | Animals | Signal Transduction - drug effects | Ubiquitin-Conjugating Enzymes - metabolism | Lipopolysaccharides - pharmacology | Cell Line, Tumor | Macrophages - drug effects | Mice | Proteasome Endopeptidase Complex - metabolism | Ubiquitin-Conjugating Enzymes - antagonists & inhibitors | Myeloid Differentiation Factor 88 - metabolism | TRAF, tumour-necrosis-factor-receptor-associated factor | HRMS, high-resolution mass spectra | K48-pUb, Lys48-linked polyubiquitin | UBE, ubiquitin-activating enzyme | IKK, IκB kinase | NEMO, NF-κB essential modifier | HEK, human embryonic kidney | TBK1, tumour-necrosis-factor-receptor-associated factor-associated NF-κB activator-binding kinase 1 | JNK, c-Jun N-terminal kinase | HOIP, haem-oxidized IRP2 ligase-1-interacting protein | LUBAC, linear ubiquitin assembly complex | ERK, extracellular-signal-regulated kinase | HTLV-1, human T-cell lymphotropic virus 1 | K63-pUb, Lys63-linked polyubiquitin | IRAK, IL-receptor-associated kinase | pUb, polyubiquitin | IκB, inhibitor of NF-κB | MALDI–TOF, matrix-assisted laser-desorption ionization–time-of-flight | GAPDH, glyceraldehyde-3-phosphate dehydrogenase | MyD88, myeloid differentiation factor 88 | DLBCL, diffuse large B-cell lymphoma | GFP, green fluorescent protein | NF-κB, nuclear factor κB | MS, tandem MS | Ubc, ubiquitin conjugating | TAK1, transforming growth factor β-activated kinase 1 | DAPI, 4′,6-diamidino-2-phenylindole | IL-1R, IL-1 receptor | DMEM, Dulbecco’s modified Eagle’s medium | HIF1α, hypoxia-inducible factor 1α | IL, interleukin | NEDD8, neural-precursor-cell-expressed developmentally down-regulated 8 | RBR, RING-between-RING, TAB, TAK1-binding protein | LPS, lipopolysaccharide | nuclear factor κB (NF-κB) | MAPK, mitogen-activated protein kinase | PAMP, pathogen-associated molecular pattern
Journal Article
Acta Pharmaceutica Sinica B, ISSN 2211-3835, 09/2015, Volume 5, Issue 5, pp. 378 - 389
Hypoxia-inducible factor-1 (HIF-1) has been recognized as an important cancer drug target. Many recent studies have provided convincing evidences of strong... 
Cancer drug discovery and development | HIF-1α inhibitors | HIF-1α | TRANSCRIPTIONAL ACTIVITY | DNA-BINDING | HIF-1 alpha | PROTEASOMAL DEGRADATION | FACTOR-I | ANTITUMOR-ACTIVITY | SIGNAL-TRANSDUCTION | SMALL-MOLECULE INHIBITORS | TUMOR-SUPPRESSOR PROTEIN | PHARMACOLOGY & PHARMACY | HIF-1 alpha inhibitors | HYPOXIA-INDUCIBLE FACTOR-1 | ENDOTHELIAL GROWTH-FACTOR | RCC, renal cell carcinoma | Ras, rat sarcoma | Raf, rapidly accelerated fibrosarcoma | EGF, epidermal growth factor | C-TAD, COOH-terminal TAD | HTS, high throughput screens | ARD-1, arrest-defective-1 | ELISA, enzyme-linked immunosorbent assay | pVHL, von Hippel-Lindau protein | LEP, leptin | ChIP, chromatin immunoprecipitation | IPAS, inhibitory PAS | IGF-BP3, IGF-factor-binding protein 3 | PAS, Per and Sim | mTOR, mammalian target of rapamycin | RT-PCR, reverse transcription polymerase chain reaction | CAC, circulating angiogenic cells | CoCl2, cobalt chloride | AKt, protein kinase B | TPT, topotecan | bHLH, basic-helix-loop-helix | LDHA, lactate dehydrogenase | GLUTs, glucose transporters | P, proline residue | ODDD, oxygen dependent degradation domain | TGF-α, transforming growth factor α | VEGF, vascular endothelial growth factor | CPTs, camptothecins | Mdm2, mouse double minute 2 homolog | PKM, pyruvate kinase M | AhR, aryl hydrocarbon receptor | K, lysine residue | IGF2, insulin-like growth factor 2 | GLUT3, glucose transporter 3 | CBP associated factor | eIF-4E, eukaryotic translation initiation factor 4E | MEK, MAPK | ADM, adrenomedullin | ARNT, aryl hydrocarbon nuclear translocator | HK2, hexokinase 2 | PHDs, prolyl-4-hydroxylases | PCAF, p300 | FIH-1, factor inhibiting HIF-1 | Review | SIRT 1, Sirtuin 1 | ERK kinase | C-MYC, myelocytomatosis virus oncogene cellular homolog | IGF-BP2, IGF-factor-binding protein 2 | N, asparagine residue | TAD, transactivation domains | HDAC, histone deacetylase | EMSA, electrophoretic mobility shift assay | LRP1, LDL-receptor-related protein 1 | Luc, luciferase | GAs, geldanamycins | HIF-1α, hypoxia-inducible factor-1α | HK1, hexokinase 1 | ID2, DNA-binding protein inhibitor | HPH, HIF-1 prolyl hydroxylases | NOS, nitric oxide synthase | N-TAD, NH2-terminal TAD | MNK, MAP kinase interacting kinase | MTs, microtubules | HRE, hypoxia response elements | ERK, extracellular signal-regulated kinase | EPO, erythropoietin | MAPK, mitogen-activated protein kinases | PI3K, phosphatidyl inositol-4,5-bisphosphate-3-kinase | DFO, deferoxamine | Top I, topoisomerase I | GLUT1, glucose transporter 1 | Hsp90, heat shock protein 90 | TGF-β3, transforming growth factor beta3 | 4E-BP1, eukaryotic translation initiation factor 4E (eIF-4E) binding protein p70 S6 kinase (S6K) | GA, geldanamycin
Journal Article
Pharmacology & therapeutics (Oxford), ISSN 0163-7258, 2017, Volume 171, pp. 30 - 42
Pericytes are a heterogeneous population of cells located in the blood vessel wall. They were first identified in the 19th century by Rouget, however their... 
Pericytes | Perivascular stem cells | Diabetic retinopathy | Diabetic nephropathy | Pericyte fibrosis | Cancer stem cells | DIABETIC-RETINOPATHY | Cancer stern cells | VEGF-A | BLOOD-BRAIN-BARRIER | MESENCHYMAL STEM-CELLS | EPITHELIUM-DERIVED FACTOR | HIGH GLUCOSE | PHARMACOLOGY & PHARMACY | STROMAL CELLS | TUMOR-GROWTH | GLYCATION END-PRODUCTS | ENDOTHELIAL GROWTH-FACTOR | Neoplasms - therapy | Animals | Diabetes Mellitus - physiopathology | Vascular Diseases - therapy | Diabetes Mellitus - therapy | Humans | Pericytes - cytology | Ischemia - therapy | Vascular Diseases - physiopathology | Ischemia - physiopathology | Molecular Targeted Therapy | Neoplasms - pathology | Blood circulation disorders | Therapeutics | Homeopathy | Materia medica and therapeutics | Impotence | Diabetic nephropathies | T cells | Muscle proteins | Cardiovascular agents | Blood coagulation factor VIII | Interleukins | Chronic kidney failure | Type 1 diabetes | Stem cells | Vascular endothelial growth factor | Mitogens | Protein kinases | Growth factors | UUO, unilateral ureteric obstruction | EGFR, EGF receptor | EMT, epithelial-mesenchymal transition | SFT, solitary fibrous tumour | DAN, diabetic autonomous neuropathy | ECM, extracellular matrix | NRF2, nuclear factor (erythroid-derived 2)-like 2 | IL-6, interleukin 6 | PSC, perivascular stem cell | BBB, blood-brain barrier | SOD, super oxide dismutase | HIF, hypoxia inducible factor | ED, erectile dysfunction | SDF-1, stromal derived factor 1 | RAGE, receptors of AGEs | CKD, chronic kidney disease | MMP, matrix metalloproteinases | MDSC, myeloid-derived suppressor cells | DN, diabetic nephropathy | TGF β, transforming growth factor β | PDL-1, programmed death-ligand 1 | ANG2, angiopoietin-2 | Olmfl3, Olfactomedin-like 3 | VEGF, vascular endothelial growth factor | AGE, Advanced Glycation End-Products | EC, endothelial cells | NG2, neural | R, ischemia-reperfusion | MSC, mesenchymal stromal cell | MF-EGF8, milk fat globule epidermal growth factor VIII | IL-8, interleukin 8 | glial antigen 2 | T1D, type 1 diabetic | PDGFb, platelet-derived growth factor B | MAPK, mitogen-activated protein kinase | PDGFRβ, platelet derived growth factor receptor β | DR, diabetic retinopathy | CNS, blood-retinal barrier | HB-EGF, heparin-binding EGF-like growth factor | HPC, hemangiopericytoma | PDR, proliferative diabetic retinopathy | DME, diabetic macular oedema | GFR, glomerular filtration rate | MI, myocardial infarction | SMA, smooth muscle actin | CSC, cancer stem cell | NPDR, non-proliferative diabetic retinopathy | T2D, type 2 diabetic | ROS, reactive oxygen species | Treg, regulatory T cells | BRB, blood-retina barrier | PKC, protein kinase C | DPN, diabetic peripheral neuropathy | TME, tumour microenvironment | ANG1, angiopoietin-1 | GSC, glioblastoma CSC | iPS, induced pluripotent stem cells | GSI, g-secretase inhibitor | FGF-9, fibroblastic growth factor 9 | PEDF, Pigment Epithelium-Derived Factor
Journal Article
Cytokine and Growth Factor Reviews, ISSN 1359-6101, 2015, Volume 26, Issue 6, pp. 673 - 685
.... The disease is initiated by the activation of the endothelium by various risk factors leading to chemokine-mediated recruitment of immune cells... 
Advanced Basic Science | Therapeutic avenues | Inflammation | Cytokines | Chemokines | Atherosclerosis | COLONY-STIMULATING FACTOR | MIGRATION INHIBITORY FACTOR | INTERLEUKIN-1 RECEPTOR ANTAGONIST | BIOCHEMISTRY & MOLECULAR BIOLOGY | MODULATES PLAQUE COMPOSITION | LOW-DENSITY-LIPOPROTEIN | NECROSIS-FACTOR-ALPHA | CELL BIOLOGY | ACUTE-PHASE RESPONSE | GROWTH-FACTOR-BETA | MARROW-DERIVED CELLS | SMOOTH-MUSCLE-CELLS | Atherosclerosis - immunology | Cytokines - metabolism | Atherosclerosis - physiopathology | Humans | Endothelium, Vascular - physiopathology | Extracellular Matrix - metabolism | Inflammation - immunology | Lipoproteins - blood | Molecular Targeted Therapy | Extracellular Matrix - chemistry | Macrophages - enzymology | Animals | Atherosclerosis - therapy | Muscle, Smooth, Vascular - chemistry | Myocardial Infarction - physiopathology | Chemokines - metabolism | Mice | Matrix Metalloproteinases - metabolism | Macrophages - immunology | Chemokines - immunology | Cytokines - immunology | Endothelium, Vascular - immunology | Inflammation - physiopathology | Development and progression | Blood lipids | Health aspects | GM-CSF, granulocyte macrophage colony-stimulating factor | ECM, extracellular matrix | RCT, reverse cholesterol transport | ICAM-1, intercellular adhesion molecule-1 | LDLr, low-density lipoprotein receptor | PECAM-1, platelet endothelial cell adhesion molecule-1 | ABC, ATP-binding cassette | IL-1RA, IL-1 receptor antagonist | ADRP, adipocyte differentiation related protein | SREBP, sterol response element binding protein | wt, wild type | G-CSF, granulocyte colony-stimulating factor | PAI, plasminogen activator inhibitor | CSF, colony-stimulating factor | PRR, pattern recognition receptor | TIMP, tissue inhibitor of metalloproteinases | NPC, Niemann-Pick disease, type C | TNF, tumor necrosis factor | TL1A, TNF-like protein 1A | NLR, NOD-like receptor | SMCs, smooth muscle cells | CR, chemokine receptor | Tregs, regulatory T cells | Survey | GDF-15, growth differentiation factor-15 | NK, natural killer | TNFSF12, TNF superfamily member 12 | IL, interleukin | NLRP3, NLR family, pyrin domain containing 3 | mmLDL, minimally modified LDL | LIGHT, homologous to lymphotoxin, exhibits inducible expression, and competes with HSV glycoprotein D for herpes virus entry mediator, a receptor expressed by T lymphocytes | TF, tissue factor | Th, T-helper | MMP, matrix metalloproteinase | OxLDL, oxidized LDL | CVD, cardiovascular disease | TLR, Toll-like receptor | DCs, dendritic cells | IL-18BP, IL-18 binding protein | miRNA, micro RNA | CANTOS, Canakinumab Anti-inflammatory Thrombosis Outcomes Study | TRAIL, TNF-related apoptosis-inducing ligand | ACAT-1, acyl-CoA acyl transferase-1 | ECs, endothelial cells | TWEAK, TNF-related weak inducer of apoptosis | TGF, transforming growth factor | LFA1, lymphocyte function-associated antigen 1 | ROS, reactive oxygen species | CIRT, Cardiovascular Inflammation Reduction Trial | LDL, low-density lipoprotein | IFN, interferon | MIF, macrophage migration inhibitory factor | SR, scavenger receptor | eNOS, endothelial nitric oxide synthase | STAT1, signal transducer and activator of transcription-1 | Fn14, fibroblast growth factor-inducible 14 | VCAM-1, vascular cell adhesion molecule-1 | LXR, liver X receptors | MHC, major histocompatibility complex | CCR2, CC-chemokine receptor-2 | NOD, nucleotide-binding oligomerization domain | VLA4, very late antigen 4 | BMT, bone marrow transplantation | SR-PSOX, SR that binds phosphatidyl serine and oxidized lipoprotein | ERK, extracellular signal-regulated kinase | SOCS, suppressor of cytokine signaling | Apo, apolipoprotein | M-CSF, macrophage-colony stimulating factor | ER, endoplasmic reticulum
Journal Article